Abstract
Background: Fumitremorgins are mycotoxins but can also inhibit cancer cells and reverse their drug resistance.
Objective: The bioactivity of prenylated cyclo-Trp-Pro dipeptides and their derivatives concerning their application in anti-cancer therapies will be discussed.
Methods: Reports on the discovery and assessment of this class of fungal compounds are compiled from literature using Google Scholar and PubMed. The bioactivities of the natural compounds are discussed with the aim of their improvement for cancer therapy.
Results: Although a number of compounds of this class have been found, only a minority of them showed bioactivity in the applied bioassays. Fumitremorgins and related compounds are active against various cancer cells but they are also mycotoxins. Some of these natural compounds can arrest cancer cells in their cell cycle and some can block ABC-transporters and reverse resistance in chemotherapy. Structure activity relationships have been deduced leading to the prediction of highly active compounds. Several easily accessible derivatives of these natural products have been discovered being highly selective and non-toxic.
Conclusion: Sophisticated screening methods, high throughput screening, metabolic engineering, and synthetic biology are novel and promising technologies for the search for highly active drugs. Rapid gene sequencing in combination with engineered biosynthetic pathways should contribute substantially to novel pharmaceutics.
Keywords: Diketopiperazines, cyclic dipeptides, fumitremorgin, cyclotryprostatin, norgeamide, anti-cancer, drug resistance, ABCG2 transporter
Current Medicinal Chemistry
Title:Fumitremorgins and Relatives – From Tremorgenic Compounds to Valuable Anti-Cancer Drugs
Volume: 25 Issue: 2
Author(s): Wolf-Rainer Abraham*
Affiliation:
- Helmholtz Centre for Infection Research, Chemical Microbiology, Braunschweig,Germany
Keywords: Diketopiperazines, cyclic dipeptides, fumitremorgin, cyclotryprostatin, norgeamide, anti-cancer, drug resistance, ABCG2 transporter
Abstract: Background: Fumitremorgins are mycotoxins but can also inhibit cancer cells and reverse their drug resistance.
Objective: The bioactivity of prenylated cyclo-Trp-Pro dipeptides and their derivatives concerning their application in anti-cancer therapies will be discussed.
Methods: Reports on the discovery and assessment of this class of fungal compounds are compiled from literature using Google Scholar and PubMed. The bioactivities of the natural compounds are discussed with the aim of their improvement for cancer therapy.
Results: Although a number of compounds of this class have been found, only a minority of them showed bioactivity in the applied bioassays. Fumitremorgins and related compounds are active against various cancer cells but they are also mycotoxins. Some of these natural compounds can arrest cancer cells in their cell cycle and some can block ABC-transporters and reverse resistance in chemotherapy. Structure activity relationships have been deduced leading to the prediction of highly active compounds. Several easily accessible derivatives of these natural products have been discovered being highly selective and non-toxic.
Conclusion: Sophisticated screening methods, high throughput screening, metabolic engineering, and synthetic biology are novel and promising technologies for the search for highly active drugs. Rapid gene sequencing in combination with engineered biosynthetic pathways should contribute substantially to novel pharmaceutics.
Export Options
About this article
Cite this article as:
Abraham Wolf-Rainer *, Fumitremorgins and Relatives – From Tremorgenic Compounds to Valuable Anti-Cancer Drugs, Current Medicinal Chemistry 2018; 25 (2) . https://dx.doi.org/10.2174/0929867324666170724103410
DOI https://dx.doi.org/10.2174/0929867324666170724103410 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Retinoids in Clinical Use
Medicinal Chemistry L-Sulforaphane Confers Protection Against Oxidative Stress in an In Vitro Model of Age-Related Macular Degeneration
Current Molecular Pharmacology Anti-Tumor Effects of Osthole on Different Malignant Tissues: A Review of Molecular Mechanisms
Anti-Cancer Agents in Medicinal Chemistry Recent Patents for Homologous Recombination Deficiency Assays Among Women with Ovarian Cancer
Recent Patents on Biotechnology Targeting the Perpetrator: Breast Cancer Stem Cell Therapeutics
Current Drug Targets Cell Metabolism Under Microenvironmental Low Oxygen Tension Levels in Stemness, Proliferation and Pluripotency
Current Molecular Medicine Detection and Therapeutic Implications of c-Met Mutations in Small Cell Lung Cancer and Neuroendocrine Tumors
Current Pharmaceutical Design Recent Advances in Drug Design of Epidermal Growth Factor Receptor Inhibitors
Current Medicinal Chemistry Treatment Related Morbidity in Cervical Cancer
Current Women`s Health Reviews A Study of Correlation between Anti-peroxidative Potential of Quercetin and Ascorbic Acid with Malondialdehyde by RP-HPLC
Current Chemical Biology Cyclin-dependent kinase Inhibitors Inspired by Roscovitine: Purine Bioisosteres
Current Pharmaceutical Design Engineered Nanoparticles for Improved Vasoactive Intestinal Peptide (VIP) Biomedical Applications
Recent Patents on Nanomedicine Imaging in Inflammatory Bowel Disease Mucosal Healing in Ulcerative Colitis: Relevance for Clinical Outcomes
Current Drug Targets Radiopharmaceutical: Revolutionary Agents for Diagnosis
Current Radiopharmaceuticals Genetically Engineered Mouse Models for Drug Discovery: New Chemical Genetic Approaches
Current Drug Discovery Technologies Matrix Metalloproteinases: New Routes to the Use of MT1-MMP As A Therapeutic Target in Angiogenesis-Related Disease
Current Pharmaceutical Design Voltage-Gated Sodium Channel Blockers as Immunomodulators
Recent Patents on CNS Drug Discovery (Discontinued) Environmental Exposure, and Other Behavioral Risk Factors in Breast Cancer
Current Cancer Therapy Reviews miR-1271 Regulates Cisplatin Resistance of Human Gastric Cancer Cell Lines by Targeting IGF1R, IRS1, mTOR, and BCL2
Anti-Cancer Agents in Medicinal Chemistry Ghrelin: New Insight to Mechanisms and Treatment of Postoperative Gastric Ileus
Current Pharmaceutical Design